NEW YORK (GenomeWeb News) – Veridex and Novartis are partnering to "encourage and facilitate" research into circulating tumor cells as potential biomarkers in metastatic prostate cancer, Veridex announced today.

As part of the deal, Veridex is supporting a prospective, single-arm, open-label study on the effect of zoledronic acid — marketed by Novartis as Zometa — on circulating tumors in patients with metastatic castration-resistant prostate cancer, or CRPC.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.